NfL as Analogue of C-Reactive Protein in Neurologic Diseases
Instructions for Use
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In the past decade, clinical research in neurologic diseases has been boosted by the possibility to quantify the degree of neuronal damage through easy-to-collect blood samples. Ultrasensitive immunoassays, such as the single-molecule array, have made it possible to measure the light chain of neurofilaments (NfL), a protein of exclusively neuronal origin, in serum and plasma, where its concentrations are roughly 40-fold lower compared with CSF.1 This sentinel of neuronal damage has been shown to detect the presence of a variety of CNS diseases, from multiple sclerosis to Alzheimer disease, frontotemporal dementia, motor neuron diseases, parkinsonism, cerebrovascular disease, and traumatic brain injury.1 Due to its ability to reflect the dynamic nature of CNS injuries, NfL has been called the “C-reactive protein” of neurology.2 Studies on blood NfL dynamics in the preclinical phases of neurologic diseases show that the signs and symptoms used to make clinical diagnoses appear late in the disease course in relation to when the pathology starts and ultrasensitive serum NfL levels can be used to identify diseases at an earlier stage.3
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
See page 919
- © 2022 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
- Reader Response: NfL as Analogue of C-Reactive Protein in Neurologic Diseases
- Khichar Shubhakaran, Senior Professor Neurolog, M D M Hospital, Dr. S. N. Medical College, Jodhpur
Submitted June 14, 2022 - Author Response: NfL as the Analogue of C-Reactive Protein in Neurologic Diseases: Instructions for Use
- Lucilla Parnetti, Full Professor of Neurology, Section of Neurology, Department of Medicine and Surgery, University of Perugia, Perugia (Italy)
- Lorenzo Gaetani, Assistant Professor, Section of Neurology, Department of Medicine and Surgery, University of Perugia, Perugia (Italy)
Submitted May 19, 2022 - Reader Response: NfL as the Analogue of C-Reactive Protein in Neurologic Diseases: Instructions for Use
- Tjalf Ziemssen, Director, Neurologist, Center of Clinical Neuroscience, Neurological University Clinic Dresden, Germany
Submitted April 15, 2022
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease
Dr. Rizwan S. Akhtar and Dr. Sarah Brooker